MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
METLIFE INC (MET) has a notice of proposed sale under Rule 144 for its common stock. An affiliate "Separate Account" plans to sell 104 shares of common stock, with an aggregate market value of $9,811.36, through Barclays on the NYSE, with an intended sale date of August 24, 2026. The filing states that there were 635,476,927 shares of common stock outstanding as of that notice. The 104 shares to be sold were acquired on December 17, 2019 by purchase from Bank of America and paid for in cash on December 19, 2019. The notice also lists several small common stock sales during the past three months by MetLife separate accounts and MetLife 401k plan vehicles.
METLIFE INC (MET) filed a notice under Rule 144 for a planned sale of its common stock for the account of MetLife Separate Account SPI, identified as an affiliate. The filing covers a proposed sale of 244 shares of MET common stock to be sold through Barclays on 08/20/2026, with an indicated value of $23,206.84.
The shares were originally acquired by purchase through Goldman Sachs on 05/29/2015. The notice also lists several small sales of MET common stock by related MetLife accounts and plans over the past three months, each involving modest share counts and dollar amounts.
MetLife, Inc. declared third quarter 2026 dividends on several series of preferred stock. The board approved a $0.31471411 quarterly dividend per share on the floating rate non-cumulative preferred stock, Series A, with a $25 liquidation preference. It also declared a $29.375 semi-annual dividend per share on the 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a $1,000 liquidation preference.
For the 5.625% non-cumulative preferred stock, Series E, MetLife declared a quarterly dividend of $351.5625 per share, or $0.3515625 per depositary share representing a 1/1,000th interest, and for the 4.75% non-cumulative preferred stock, Series F, a quarterly dividend of $296.875 per share, or $0.296875 per depositary share. These dividends are payable on September 15, 2026 to shareholders of record as of August 31, 2026.
MetLife, Inc., as an institutional investment manager, submitted a Form 13F report covering certain equity holdings over which its investment subsidiaries exercise investment discretion. MetLife states that it disclaims direct investment discretion and reports positions to the extent its ownership in these subsidiaries creates a reporting obligation. The report is filed as a 13F Combination Report and summarizes 6 portfolio entries with an aggregate reported value of $13,089,220.
MetLife, Inc.’s Board of Directors, acting as an entity, reports beneficial ownership of 102,098,469 shares of MetLife common stock, representing 16.1% of the outstanding class as of July 31, 2026. The shares are held in the MetLife Policyholder Trust for eligible policyholders and permitted transferees.
The Trustee holds legal title and votes the shares largely according to the Board’s recommendations, which causes the Board to be deemed a beneficial owner for voting purposes. Policyholder beneficiaries hold Trust Interests, direct the receipt of dividends and sale proceeds on their allocated shares, and may withdraw shares, including to participate in tender or exchange offers.
MetLife, Inc. reported consolidated revenues of $38,228 million and net income of $1,941 million for the six months ended June 30, 2026, with diluted EPS of $2.83, compared with $2.32 a year earlier. Total assets were $759,372 million and total equity was $27,741 million at June 30, 2026.
Total consolidated adjusted earnings were $3,235 million for the first half, led by Group Benefits ($942 million), Asia ($907 million) and RIS ($828 million). The company highlighted a strategic reorganization that elevated MetLife Investment Management to a reportable segment and completed the PineBridge Investments acquisition for $885 million. A pending sale of MetLife Ukraine resulted in a $65 million impairment loss, net of income tax, recorded in net investment gains (losses). Operating cash flow was $4,915 million, and policyholder account balances were $245,458 million.
MetLife, Inc. reported second quarter 2026 results and its board approved a new $3.0 billion common stock repurchase authorization.
Net income was $705 million, or $1.09 per share, up 6% per share from a year earlier. Adjusted earnings rose 15% to $1.6 billion, with adjusted EPS up 20% to $2.43. Premiums, fees and other revenues grew 7% to $13.7 billion, and net investment income increased 18% to $6.7 billion. Adjusted return on equity reached 17.0% for the second straight quarter. Book value per share was $38.59, with adjusted book value per share of $57.71.
All operating segments contributed, including Group Benefits adjusted earnings of $503 million (up 25%), Retirement and Income Solutions $377 million (up 2%), Asia $420 million (up 21%), Latin America $268 million (up 15%), and EMEA $108 million (up 8%). MetLife Investment Management reported adjusted earnings of $57 million and total assets under management of $748.1 billion, up 20%. The company returned over $1.1 billion to shareholders through share repurchases and common dividends in the quarter, while holding company cash and liquid assets totaled $3.4 billion.
MetLife, Inc. released preliminary figures for its variable investment income for the quarter ended June 30, 2026. The company currently estimates this income will be between $220 million and $270 million (pre-tax), which it contrasts with its full-year 2026 variable investment income guidance of approximately $1.6 billion (pre-tax).
Variable investment income reflects returns from private equity, real estate and other funds, as well as prepayment fees. MetLife emphasizes that these numbers are unaudited, based on information available to management as of the disclosure date, and may differ materially once full closing procedures are complete. The company cautions readers not to rely on these estimates as a substitute for full U.S. GAAP financial statements or to infer performance for future periods.
MetLife (proposed sales reported on Form 144) — Multiple affiliated accounts reported proposed sales of Common Stock via Form 144. The excerpt lists specific proposed sale entries with dates and amounts, including 121 shares for 04/02/2026 ($8,557.12), 144 shares for 05/05/2026 ($11,505.60), and other transactions through 06/18/2026.
The transactions are attributed to named accounts such as Separate Account, Separate Account II, Separate Account SPI, and MetLife 401k Plan Trust-Large Cap Equity Index. The filing lists broker and trade details for earlier sales and indicates cash sales in the past three months. This Form 144 disclosure notifies the market of proposed resale activity by related accounts.
MetLife, Inc. shareholders held their annual meeting on June 16, 2026. Investors elected eleven directors to terms expiring at the 2027 annual meeting, with each nominee receiving a large majority of votes cast. Shareholders also ratified Deloitte & Touche LLP as MetLife’s independent auditor for 2026.
In addition, shareholders approved on an advisory (non-binding) basis the compensation paid to MetLife’s Named Executive Officers, as described in the 2026 proxy statement. Overall, the voting results indicate broad shareholder support for the company’s board, executive pay program, and external auditor.